Background {#Sec1}
==========

The increasing antimicrobial resistance remains a major threat worldwide \[[@CR1]\]. Extended-spectrum beta-lactamase-producing *Enterobacteriaceae* (ESBL-E) fecal carriage is increasing, especially in long-term care facilities and ICU \[[@CR2]--[@CR4]\]. The ESBL-E dissemination is of paramount importance since ESBL-E infections lead to increased healthcare costs, length of stay and mortality \[[@CR5]--[@CR8]\]. ESBL-E dissemination was first due to clonal outbreaks in hospital settings of TEM- and SHV-producing *Enterobacteriaceae*, and cross-transmission was highly involved in the outbreaks in ICU leading to the enforcement of hygiene procedures \[[@CR9]--[@CR11]\]. Systematic ESBL-E fecal carriage screening in ICU has been proposed as a standard of care by some societies as the provided information was thought to be useful to guide hygiene procedures \[[@CR9]\]. More recently, ESBL gene epidemiology has been totally overhauled by the emergence of CefoTaXimase-München (CTX-M) enzymes which became the most predominant ESBL type worldwide in the early 2000s \[[@CR12]\]. Contact precautions were still recommended for hospitalized ESBL-E fecal carriers to prevent nosocomial spread \[[@CR13]\]. Therefore, systematic ESBL-E fecal carriage screening at admission was still considered as a standard of care to reduce guide contact precautions and decrease the incidence of hospital-onset ESBL-E clinical isolates \[[@CR14], [@CR15]\]. Unfortunately, despite those precautions, a steady increase of ESBL-E rate has been reported in hospital settings but also in the community which can range from 1--6% in Europe and North America to 60% in India \[[@CR2], [@CR16]\]. The paradigm of ESBL-E dissemination occurring only in hospital settings by clonal outbreaks has been dramatically changed with the ESBL-E dissemination now occurring everywhere, both in community and hospital settings, enhancing the need for further evaluation of contact precautions' efficacy.

Another interest of systematic screening of ESBL-E fecal carriage in ICU could also be to guide the empiric treatment of ICU-acquired infections. In fact, this treatment is often challenging, and carbapenems have emerged as the gold standard as they are almost always active on ESBL-E. However, carbapenems use leads to the emergence of *Enterobacteriaceae* resistant to carbapenems including non-fermenting Gram-negative, which cause almost half of culture-positive ventilator-associated pneumonia (VAP) in ESBL-E carriers \[[@CR17]--[@CR19]\]. As a consequence, alternative strategies to spare carbapenems are urgently needed \[[@CR20]\]. ESBL-E fecal carriage has been suggested as a tool to guide the prescription of carbapenems for empiric antimicrobial therapy because of the suspected link between colonization and infection. Nevertheless, the predictive value of ESBL-E fecal carriage for helping the clinician to tailor the empirical antimicrobial therapy and its impact on the use of carbapenems is still a matter of debate.

Systematic fecal carriage screening of ESBL-E could also help to guide decolonization procedures. As a matter of fact, gut microbiota is now considered as the main source of ESBL-E dissemination \[[@CR21]\]. Changes in the composition of the gut flora, due in particular to antibiotics and critical illness, can happen silently, leading to the selection of highly resistant bacteria including ESBL-E which can remain for months in the gut of the carrier without causing any symptoms or translocate through the gut epithelium, induce healthcare-associated infections, undergo cross-transmission to other individuals, and cause limited outbreaks. However, data about gut microbiota modulation (by selective decontamination or by fecal microbiota transplantation (FMT)) to eradicate ESBL-E fecal carriage are scarce.

We propose here to systematically review the evidence to recommend or not such systematic ESBL-E fecal carriage screening in ICU regarding the guidance of hygiene procedures, of empirical antimicrobial therapy for ICU-acquired infections and of selective decontamination strategy.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

We searched the MEDLINE database for English language articles published from the inception of the database to February 15, 2019. A combination of MeSH/Emtree and title/abstract keywords was used. The search terms were "ESBL," "ESBL-E," "ESBLE," "extended spectrum beta-lactamase," "ICU" with non-relevant terms "neonatal," "pediatric," "children," and "infants".

Eligibility criteria {#Sec4}
--------------------

Studies were considered suitable for inclusion in this systematic review if (1) they enrolled ICU ESBL-E fecal carriers in a non-outbreak situation, (2) they assess the rate of ESBL-E cross-transmission in ICU, (3) they evaluate the efficacy of contact precautions to limit the spread of ESBL-E, (4) they assess the link or the prognostic value of ESBL-E carriage for subsequent ESBL-E infection, (5) they assess the efficacy of selective decontamination strategy to limit subsequent ESBL-E cross-transmission or infection, (6) all the patients were adults, and (7) they were written in English. If the studies lacked outcome data or provided only the prevalence of ESBL-E colonization or infection, they were excluded. If the full text could not be retrieved or if the article was a commentary or a review or an *erratum*, it was excluded.

Selection of studies and data extraction {#Sec5}
----------------------------------------

All the available data were extracted from each study by two investigators (DG and RP) independently according to the aforementioned inclusion criteria, and any differences were resolved by discussion with a third investigator (JRZ). The following data were collected from each study: the name of the first author, publication year, study design, number of patients, primary outcome, and risk factors for the primary outcome.

Results {#Sec6}
=======

Study selections {#Sec7}
----------------

Using the previously described request in MEDLINE database, 330 articles were referenced. Every abstract was read and 39 articles that appeared to address issues relevant for this review were selected for full-text assessment. After full-text assessment, 25 studies were included in the systematic review (Fig. [1](#Fig1){ref-type="fig"}). Seven were relevant regarding the risk of ESBL-E cross-transmission (Table [1](#Tab1){ref-type="table"}), 4 regarding the evaluation of hygiene procedures' efficacy (Table [2](#Tab2){ref-type="table"}), 10 assessed the link between colonization and infection or the prognostic value of ESBL-E carriage to guide the empirical antimicrobial therapy (Table [3](#Tab3){ref-type="table"}), and 4 the efficacy of a selective decontamination strategy (SD) (Table [4](#Tab4){ref-type="table"}).Fig. 1Flowchart of the study selection processTable 1Low level of ICU ESBL-E cross-transmission in a non-outbreak situationYearAuthorsDesign*N*OutcomeBrief results2017Repessé et al. \[[@CR28]\]Cohort study470ESBL-E fecal carriage\
Cross-transmission assessed by epidemiology and ESBL gene sequencing62/470 (13.2%) of imported ESBL-E fecal carriage\
9/221 (4.1%) of acquired ESBL-E fecal carriage\
2/9 acquisitions were likely to be due to cross-transmission2016Alves et al. \[[@CR27]\]Cohort study309ESBL-E fecal carriage\
Cross-transmission assessed by epidemiology, rep-PCR and plasmid PCR25/309 (8%) of imported ESBL-E fecal carriage\
19/309 (6.5%) of acquired ESBL-E fecal carriage\
1/19 acquisition was likely to be due to cross-transmission2015O'Connell et al.\
\[[@CR26]\]Cohort study316ESBL-E fecal carriage\
Cross-transmission assessed by epidemiology and PFGE50/316 (15.8%) of ESBL-E fecal carriage\
2 cases of suspected cross-transmission for *E.coli* and 2 for *E. cloacae* but only 1 (*E. cloacae*) occurred in ICU2014Kim J et al. \[[@CR25]\]Cohort study347Acquisition of ESBL-E by epidemiology and PFGE98/347 (28.2%) of imported ESBL-E fecal carriage\
11/91 (12.1%) of acquired ESBL-E fecal carriage in ICU\
No case of cross-transmission2007Harris et al. \[[@CR24]\]Cohort study1806Acquisition of ESBL-producing *E. coli* by epidemiology and PFGE97/1806 (5%) of ESBL-E fecal carriers including as follows:\
23/97 (24%) of acquired ESBL-producing *E. coli* fecal carriage\
3/23 (13%) acquisitions were likely to be due to cross-transmission2004Thouverez et al.\
\[[@CR23]\]Cohort study2883Acquisition of ESBL-E by epidemiology and PFGE9/28 cases of ESBL-E acquisition explained by cross-transmission1996Gori et al. \[[@CR22]\]Cohort study8640Acquisition of ESBL-producing *K. pneumoniae* by antibiotype, plasmid content, PFGE, and RAPD45/8640 (0.5%) ESBL-E fecal carriage\
4 ESBL-producing *K. pneumoniae* clonal groups among which 2 are associated with clusters of cross-infection involving 5 and 12 patients*ESBL-E* extended-spectrum beta-lactamase-producing *Enterobacteriaceae*, *ICU* intensive care unit, *PFGE* pulsed-field gel electrophoresis, *RAP* rapid amplified polymorphic DNA, *rep-PCR* repetitive-element polymerase chain reactionTable 2Efficacy of contact precautions on ICU ESBL-E dissemination in a non-outbreak situationYearAuthorsDesign*N*OutcomeBrief results2018Jalalzaï et al. \[[@CR30]\]Unicentric, retrospective, uncontrolled before-and-after study524 SCP\
545 non-SCP with SPICU-acquired ESBL-E infections\
ICU deathsNo independent impact on ESBL-E infections of cessation of admission screening (adjusted OR 1.16, 95% CI 0.38--3.50, *p* = 0.79)\
nor on in-ICU death (SHR 1.22, 95% CI 0.93--1.59, *p* = 0.15)2017Kardas-Stoma et al. \[[@CR32]\]Cost-effectiveness analysisNAICU-acquired ESBL-E fecal carriage\
ICU-acquired ESBL-E infectionsUniversal screening and contact precautions for ESBL-E fecal carriers vs base care, per 100 admissions\
12 vs 15 ICU-acquired ESBL-E fecal carriage\
4 vs 5 ICU-acquired ESBL-E infections2017Renaudin et al. \[[@CR31]\]Prospective non-inferiority before-and-after study1547 CP 1577 SPICU-acquired ESBL-E fecal carriageIncidence densities respectively during CP and SP:\
2.7 (95% CI 1.78--3.62), 2.06 (95% CI 1.27--2.86) per 1000 patient-days; *p* 0.004 for non-inferiority2014Derde et al. \[[@CR29]\]Prospective, randomized, interrupted, time series study8501ICU-acquired ESBL-E fecal carriage with and without CPIncidence rate ratio: 0.994 (0.968--1.021; *p* 0.66) comparing with and without CP*CP* contact precautions, *HH* hand hygiene, *ICU* intensive care unit, *PFGE* pulsed-field gel electrophoresis, *rep-PCR* repetitive-element Polymerase chain reaction, *SP* standard precautions, *SCP* screening periodTable 3Evaluation of ESBL-E fecal carriage to tailor empirical antimicrobial therapyYearAuthorsDesign*N*OutcomeBrief results2018Jalalzaï et al. \[[@CR30]\]Monocentric, retrospective, before-and-after study524 SCP 545 non-SCPCarbapenem consumptionDecrease in carbapenem exposure in patients without ESBL-E infection during the non-SCP (75 vs 61 carbapenem-days per 1000 patient-days, *p* = 0.01)2018Barbier et al. \[[@CR39]\]Inception cohort of a multicenter prospective database318ESBL-E VAP18 ESBL-E VAP for 361 (5%) ventilator-associated complications among ESBL-E fecal carriers2018Houard et al. \[[@CR40]\]Monocentric, retrospective cohort study410ESBL-E VAPPrevious ESBL-E fecal carriage as the only independent risk factor \[OR 23; 95% CI (10--55), *p* \< 0.001\] Predictive value of ESBL-E fecal carriage for subsequent ESBL-E VAP: PPV 43.6%, NVP 97.3%2018Liu et al. \[[@CR35]\]Monocentric, retrospective nested case-control study9015ICU-acquired ESBL-E BSI42 ESBL-E BSI among 9015 ESBL-E fecal carriers (0.5%) Independent risk factors associated with subsequent ESBL-E BSI: Antibiotic in the past 72 h: Penicillin (OR 12.076; 95% CI 1.397--104.251, *p* 0.024) Cephalosporin (OR 6.900; 95% CI 1.493--31.852, *p* 0.013) Carbapenem (OR 5.422; 95% CI 1.228--23.907, *p* 0.026) Previous ICU stay (OR 1.041; 95% CI 1.009--1.075, *p* 0,012) Maximum body temperature (OR 8.014; 95% CI 2.408--26.620, *p* 0.001)2017Razazi et al. \[[@CR37]\]Monocentric, prospective cohort study6303ICU-acquired ESBL-E pneumonia\
Predictive factors for ESBL-E pneumonia among carriers48/843 (6%) ESBL-E fecal carriers has subsequent ICU-acquired ESBL-E pneumonia\
48/111 (43%) of ICU-acquired pneumonia among ESBL-E fecal carriers were due to ESBL-E\
SAPSII at admission \> 43 \[OR 2.81 (1.16--6.79)\]\
Colonization with *Enterobacter* sp. or *K. pneumoniae* \[OR 10.96 (2.93--41.0)\]\
Receipt of \> 2 days of AMC \[OR 0.24 (0.08--0.71)\]2017Carbonne et al. \[[@CR38]\]Multicenter, retrospective cohort study1503ESBL-E pulmonary colonizationESBL-E fecal carriage predictive values for ESBL-E pulmonary colonization:\
Early (≤ 5 days): NPV 99.2% (95% CI \[98.7;99.6\]), PPV 14.5% (95% CI \[12.8;16.3\])\
Late (\> 5 days): NPV 93.4% (95% CI \[91.9;95.0\]), PPV 34.4% (95% CI \[31.4;37.4\])2016Barbier et al. \[[@CR41]\]Cause-specific hazard model based on prospective data16,374ICU-acquired ESBL-E infection\
Carbapenem exposure98/594 (16.4%) ESBL-E fecal carriers had subsequent ICU-acquired ESBL-E infection\
627, 241 and 69 carbapenem-days per 1000 patient-days for respectively infected ESBL-E carriers, non-infected ESBL-E carriers and non ESBL-E carriers2016Bruyère et al. \[[@CR19]\]Monocentric, retrospective cohort study587ESBL-E VAPESBL-E fecal carriage predictive values for ESBL-E VAP:\
PPV 41.5%, NPV 99.4%2012Razazi et al. \[[@CR34]\]Monocentric, prospective, cohort study610ICU-acquired ESBL-E infection10% of the first episodes of ICU-acquired infections are due to ESBL-E\
27% of the second episodes of ICU-acquired infections are due to ESBL-E2006Martins et al. \[[@CR36]\]Monocentric prospective cohort study231ICU-acquired ESBL-producing *K. pneumoniae* pneumoniaPrevious ESBL-production *K. pneumoniae* is an independent risk factor ICU-acquired ESBL-producing *K. pneumoniae* pneumonia (OR 60.6; 95% CI 56.33--578.73)*AMC* amoxicillin/clavulanic acid, *BSI* bloodstream infection, *ESBL-E* extended-spectrum beta-lactamase-producing *Enterobacteriaceae*, *ICU* intensive care unit, *NPV* negative predictive value, *PPV* predictive positive value, *SCP* screening period, *SAPSII* Simplified Acute Physiology Score II, *VAP* ventilator-associated pneumoniaTable 4Efficacy of selective decontamination for ESBL-E fecal carriage among ICU patientsYearAuthorsDesignDecontamination*N*OutcomeBrief results2018Wittekamp et al. \[[@CR46]\]Randomized controlled trialCHX 2%\
SOD by mouthpaste (colistin, tobramycin, nystatin)\
SDD by the same mouthpaste and gastrointestinal suspension)8665ICU-acquired ESBL-E BSIaHR vs baseline:\
CHX 1.13 (95% CI 0.68--1.88)\
SOD 0.89 (95% CI 0 .55--1.45)\
SDD 0.70 (95% CI 0.43--1.14)2016Camus et al. \[[@CR44]\]Observational\
Before-afterSDD by as follows:\
Colistin\
Tobramycin\
Amphotericin B5250Rates of acquired infections caused by AGNB\
Rates of ESBL-E fecal carriage acquisitionDiminution of the incidence rate of acquired infections caused by AGNB (1.59 vs 5.43 per 1000 patient-days, *p* \< 0.001)\
Diminution of the acquisition rate of ESBL-E fecal carriage (OR = 0.94 \[0.88--1.00\], *p* = 0.04)2005Troché et al. \[[@CR43]\]Prospective observational cohort studySDD by 2 among the following:\
Erythromycin\
Neomycin\
Polymyxin E2235Rates of ESBL-E fecal carriage acquisitionDiminution of the acquisition rate of ESBL-E fecal carriage from 5.5 cases per 1000 patient-days during the first 3 years to 1.9 cases during the last 3 years (*p* \< 0.05)1998Decré et al. \[[@CR45]\]Prospective controlled cohort studySDD by as follows:\
Erythromycin Polymyxin E65Incidence and infection with ESBL- *K. pneumoniae*Selective digestive decolonization failed to reduce the incidence of acquisition of ESBL-producing *K. pneumoniaeAGNB* multidrug-resistant aerobic Gram-negative bacilli, *aHR* adjusted Hazard ratio, *BSI* bloodstream infection, *CHX* chlorhexidine, *SDD* selective digestive decontamination, *SOD* selective oral decontamination

ESBL-E fecal carriage and the risk of cross-transmission in ICU in a non-outbreak situation {#Sec8}
-------------------------------------------------------------------------------------------

The first study demonstrating ICU ESBL-E cross-transmission in a non-outbreak situation describes two clones responsible for clusters of 5 and 12 patients. Nevertheless, this study included patient in 1990 and 1991 and did not focused on carriage but infection \[[@CR22]\]. Another study involved 2883 patients with 28 (0.97%) ESBL-E carriers. Only 9/28 cases of ESBL-E were explained by cross-transmission despite the fact that the screening method was suboptimal limiting their impact on the prevention of ESBL-E dissemination \[[@CR23]\]. These results were consistent with another one detecting 97/1806 (5%) of ESBL-E fecal carriers including 23/97 (24%) of ICU-acquired ESBL-producing *E. coli* fecal carriage with only 3/23 (13%) acquisitions likely to be due to cross-transmission \[[@CR24]\]. Similar results were demonstrated even in a higher prevalence situation (ESBL-E carriage at admission: 98/347 (28.2%)), with an acquisition rate of 12.1% (11/91) without any case of cross-transmission \[[@CR25]\]. Another study based on pulsed-field gel electrophoresis (PFGE), revealed two cases of suspected cross-transmission for *E. coli* and two for *E. cloacae* in a setting with 50/316 (15.8%) of ESBL-E fecal carriage from patients on the liver transplantation, ICU, and hematology/oncology wards. Nevertheless, only one case of suspected cross-transmission (*E. cloacae*) occurred in ICU \[[@CR26]\]. In other studies, cross-transmission has also been shown to be a rare event (5% of ESBL-E acquisition) \[[@CR27]\], even in an ICU with no single room \[[@CR28]\]. The occurrence of ESBL-E acquisition despite limited cross-transmission suggests limits to hygiene procedure efficacy in controlling ESBL-E dissemination in a non-outbreak situation and other mechanisms of dissemination which we still have to investigate.

ESBL-E fecal carriage and hygiene procedures in a non-outbreak situation {#Sec9}
------------------------------------------------------------------------

A large multicenter study in 13 European ICU testing the effect of rapid screening and isolation of carriers with contact precautions did not find any impact on ESBL-E acquisition, but the study was led in the context of a sustained high level of compliance to hand hygiene and chlorhexidine bathings \[[@CR29]\]. In another study, cessation of contact isolation procedures had no independent impact on ESBL-E infections (adjusted OR 1.16, 95% CI 0.38--3.50, *p* = 0.79) nor on in-ICU death (SHR 1.22, 95% CI 0.93--1.59, *p* = 0.15) \[[@CR30]\]. These results were consistent with a previous study which found that discontinuing contact precautions did not increase ICU-acquired ESBL-E fecal carriage (incidence densities respectively during contact vs standard precautions: 2.7 (95% CI 1.78--3.62) and 2.06 (95% CI 1.27--2.86) per 1000 patient-days; *p* 0.004 for non-inferiority) in an ICU with single rooms with dedicated equipment, strict application of hand hygiene, medical and paramedical leadership, and good antibiotic stewardship. \[[@CR31]\].

A cost-effectiveness analysis showed that an improved compliance with hand hygiene is the most cost-saving strategy to prevent the transmission of ESBL-E. Screening and cohorting had comparable effectiveness but were more expensive; screening and contact precautions were the least effective strategy \[[@CR32]\].

To summarize, these results together suggest that cross-transmission does not seem any more to be the main source of ESBL-E acquisition in ICU. Moreover, a universal standard precaution strategy seems to be sufficient to control the risk of cross-transmission. The relevance of a systematic ESBL-E fecal carriage screening policy in ICU to guide hygiene procedures is now questioned (Additional file [1](#MOESM1){ref-type="media"}).

ESBL-E fecal carriage prognostic value for subsequent ICU-acquired ESBL-E infections in a non-outbreak situation {#Sec10}
----------------------------------------------------------------------------------------------------------------

Another discussed interest of systematic screening of ESBL-E fecal carriage could be to guide empiric antimicrobial therapy in case of subsequent infection among carriers. The most investigated ICU-acquired infections are VAP and bloodstream infections (BSI) as they are the more frequent ones \[[@CR33]\]. Among ESBL-E fecal carriers in ICU, one study found that 10% and 27% of first and second episodes of ICU-acquired infections \[[@CR34]\] and another that even 40% of VAP are due to ESBL-E \[[@CR19]\].

Regarding BSI, a recent study conducted in China found a proportion of 0.5% of ESBL-E fecal carriers developing subsequent ESBL-E BSI in ICU (42/9015). Independent risk factors associated with subsequent ESBL-E BSI were antibiotic use in the past 72 h (penicillin \[OR 12.076; 95% CI 1.397--104.251, *p* 0.024\], cephalosporin \[OR 6.900; 95% CI 1.493--31.852, *p* 0.013\], carbapenem \[OR: 5422; 95% CI 1.228--23.907, *p* 0.026\]), previous ICU stay (OR 1.041; 95% CI 1.009--1.075, *p* 0,012), and maximum body temperature (OR 8014; 95% CI 2.408--26.620, *p* 0.001) \[[@CR35]\]. Nevertheless, as a case is diagnosed by a positive blood culture, antimicrobial therapy and maximum body temperature could only be the signal of the on-going infection with empiric treatment initiated as ESBL-E BSI are compared with non-infected ESBL-E fecal carriers.

Regarding risk factors for VAP, ESBL-producing *Klebsiella pneumoniae* was found to be an independent risk factor ICU-acquired ESBL-producing *K. pneumoniae* pneumonia (OR 60.6; 95% CI 56.33--578.73) \[[@CR36]\]. Other identified independent risk factors for ESBL-E pneumonia among ESBL-E fecal carriers were SAPS II at admission \> 43 \[OR 2.81 (1.16--6.79)\] and colonization with *Enterobacter* sp. or *K. pneumoniae* species \[OR 10.96 (2.93--41.0)\] whereas receipt of \> 2 days of amoxicillin/clavulanic acid during the ICU stay was protective \[OR 0.24 (0.08--0.71)\] \[[@CR37]\]. Despite these identified risk factors, individual prediction of subsequent ESBL-E VAP among ESBL-E fecal carriers remains difficult and prognostic values will be discussed thereafter.

Regarding ESBL-E pulmonary colonization, ESBL-E fecal carriage has an excellent negative predictive value (NPV) (99.2%, 95% CI \[98.7,99.6\] for ≤ 5 days and 93.4%, 95% CI \[91.9,95.0\] for \> 5 days) despite a poor positive predictive value (PPV) (14.5% \[95% CI 12.8, 16.3\] and 34.4% \[95% CI \[31.4, 37.4\]), for the early and late groups respectively \[[@CR38]\].

Nevertheless, pulmonary colonization does not mean infection. A monocentric prospective study found 111 (13%) patients among 843 ESBL-E fecal carriers who developed ICU-acquired pneumonia of whom 48 (43%) had ESBL-E pneumonia (6% of carriers). Patients with ESBL-PE pneumonia in this study had a higher SOFA score (*p* = 0.037) and more frequent septic shock at pneumonia onset (*p* = 0.047) than patients with pneumonia due to another germ \[[@CR37]\]. Even if this article also identified risk factors, it remains very difficult to predict which patient will suffer from a ESBL-E VAP or not. Enhancing this result, an inception cohort of the prospective database OUTCOMEREA showed that infectious-related ventilator-associated complications among ESBL-E fecal carriers mostly reflect non-VAP events (18/361, 13%) with only 18/361 (5%) ESBL-E VAP but that they are a major driver of carbapenem consumption \[[@CR39]\]. Regarding predictive values, a retrospective monocentric study showed a 41.5% PPV and a 99.4% NPV \[[@CR19]\]. Another study confirmed prior ESBL-E fecal carriage to be the only independent risk factor for subsequent ESBL-E VAP \[OR 23 (95% CI 10--55)\] with a PPV of 43.6% and a NPV of 97.3%. Duration of mechanical ventilation, length of ICU stays, and mortality rates (55.8% vs 50%, *p* = 0.48) were similar in ESBL-E VAP, compared with VAP due to other bacteria \[[@CR40]\]. Because of these excellent NPV, some authors have suggested that systematic ESBL-E fecal carriage screening could help to limit the use of carbapenems, but this assertion is now contradicted.

Jalalzaï et al. assessed carbapenem consumption after cessation of screening for intestinal carriage of ESBL-E during two consecutive 1-year period (with and without systematic screening with respectively 524 and 545 patients) \[[@CR30]\]. An admission during the no-systematic screening period exerted no independent impact on the hazards of ESBL-E infections and in-ICU death. The exposure to carbapenems in patients without ESBL-E infection even decreased between the systematic screening and no-systematic screening periods (75 versus 61 carbapenem-days per 1000 patient-days, *p* = 0.01). These results are consistent with a prospective multicentric study revealing that ESBL-E infections are rather infrequent in carriers and that carbapenem exposure was increased among ESBL-E carriers without infection. ESBL-E carriers even without infections also had a delayed discharge, thereby amplifying the selective pressure and the colonization pressure in ICU \[[@CR41]\].

To summarize, the link between ESBL-E colonization and subsequent ESBL-E infection seems to be real as consistently observed by several different teams. Nevertheless, subsequent ESBL-E infections are a rare event which is almost unpredictable. An empirical antimicrobial therapy guided on ESBL-E carriage status leads to an overconsumption of carbapenems without a clinical benefit. A systematic screening policy of ESBL-E fecal carriage in ICU to guide empirical antimicrobial therapy is now questioned. Further studies are needed to better understand the link between colonization and infection and to assess if we can improve the prediction of subsequent ESBL-E infections. Disturbances of gut microbiota could be part of the explanation, and so selective decontamination has been evoked as a tool to modulate the gut microbiota and to eradicate multi-drug resistant bacteria fecal carriage \[[@CR21], [@CR42]\].

### ESBL-E fecal carriage and selective decontamination in ICU in a non-outbreak situation {#Sec11}

One prospective observational cohort study in a surgical ICU of a tertiary teaching hospital using 2 antibiotics among erythromycin, neomycin, or polymyxin E in 37 ESBL-E fecal carriers (2235 patients included) suggested a diminution of the acquisition rate of ESBL-E fecal carriage from 5.5 cases per 1000 patient-days during the first 3 years to 1.9 cases during the last 3 years (*p* \< 0.05) but it was a secondary outcome \[[@CR43]\]. Additionally, an observational single-center study found a diminution of the incidence rate of acquired infections caused by multidrug-resistant aerobic Gram-negative bacilli (1.59 vs 5.43 per 1000 patient-days, *p* \< 0.001) and a diminution of the acquisition rate of ESBL-E fecal carriage (OR = 0.94 \[0.88--1.00\], *p* = 0.04) \[[@CR44]\]. Another prospective controlled cohort study with decolonization by erythromycin and polymyxin E concluded that selective digestive decolonization (SDD) failed to reduce the incidence of acquisition of ESBL-producing *K. pneumoniae* \[[@CR45]\]. Nevertheless, these studies did not assess the efficacy of SDD especially for the ESBL-E carriers. A recent multicenter prospective study including 8665 patients compared the efficacy of chlorhexidine 2% vs selective oral decontamination (SOD) by mouthpaste (colistin, tobramycin, nystatin) vs SDD by the same mouthpaste and gastrointestinal suspension to prevent ESBL-E bloodstream infections but among every ventilated patients in ICU and not only ESBL-E carriers. Compared to baseline care, they did not find any strategy to be efficient (adjusted hazard ratios: CHX 1.13 (95% CI 0.68--1.88), SOD 0.89 (95% CI 0.55--1.45), SDD 0.70 (95% CI 0.43--1.14) \[[@CR46]\].

Because of the lack of high-quality evidence of selective decontamination efficacy (oral and/or digestive) and concerns about the emergence of resistance to the antimicrobials used, European guidelines recommend against decolonization strategies for ICU ESBL-E fecal carriers and call for more research \[[@CR47]\]. According to current knowledge, it does not seem relevant to have a systematic ESBL-E fecal carriage screening policy to guide selective decontamination strategy as ESBL-E gut decolonization by antibiotics are not validated and so not recommended. Nevertheless, the impact of SDD on ESBL carriage was only evaluated in studies performed in western countries. This field seems to be helpful and should be better explored.

Discussion {#Sec12}
==========

A universal standard precaution strategy seems to be sufficient to control the risk of ESBL-E cross-transmission even in ICU. A systematic screening policy to guide contact precautions does not appear to be useful and cost-effective. Therefore, it should be kept in mind that the studies reported here assessed a non-outbreak situation in western countries. A study assessing the ESBL-E respiratory colonization in Sri Lanka suggested a higher cross-transmission rate but no data are provided about the imported or acquired status of ESBL-E colonization \[[@CR48]\]. Further studies are needed to assess the rate of cross-transmission and the efficacy of hygiene procedures in non-western countries which have a higher prevalence of ESBL-E \[[@CR2], [@CR16]\]. Moreover, the four studies presented in Table [2](#Tab2){ref-type="table"} have some methodological limitations even if they all draw the same conclusions without any increase in ESBL-E infections after cessation of contact precautions for strict standard precautions and that studies conducted in a non-ICU setting discussed thereafter conclude the same way.

Regarding the efficacy of hygiene procedures in non-ICU setting, a quasi-experimental study showed that contact precautions prevent from outbreaks but have no impact on nosocomial ESBL incidence in a non-outbreak situation \[[@CR49]\]. Then, cessation of contact precautions for ESBL-producing *E.coli* was first demonstrated to be safe among non-ICU hospitalized patients in double-bed rooms with another patient colonized or infected with an ESBL-E \[[@CR50]\] and was confirmed by the absence of cross-transmission with the respect of the sole standard hygiene precautions \[[@CR51]\]. In addition, a study showed no difference between standard and contact precautions in the incidence of ESBL-E in hospital settings \[[@CR52]\]. Besides the lack of efficacy, contact precautions are associated with adverse effects including patients' psychological distress or medical errors \[[@CR53], [@CR54]\]. Another point is that even if cross-transmission can be a cause of ESBL-E carriage acquisition, it remains a rare event in western countries ICU under strict hygiene procedures. For instance, even in a study with a large proportion of cross-transmission among ICU-acquired ESBL-E carriage acquisition (3/23, 13%), in fact only 3/1806 (0.17%) patients admitted in ICU during the study period experienced ESBL-E cross-transmission \[[@CR24]\]. Moreover, even one case of cross-transmission will always be concerning and thorough standard procedures are absolutely needed.

Besides, the ability for spreading of the different species of *Enterobacteriaceae* could be variable with a special concern for *K pneumoniae*. Some authors suggest it could be 3.7 times more prone to cross-transmission than *E.coli* \[[@CR55]\]. Nevertheless, the mathematical model assuming a 100% sensitivity and specificity for microbiological tests and the absence of interaction between *E. coli* and non-*E. coli* bacteria cannot be fully realistic and so limit the validity of these results. It remains also unclear if this difference of transmissibility relies on bacteria intrinsic virulence or patients' frailty. Colonization seems to occur in patients with many comorbidities, invasive procedures, and antimicrobial exposure, who have a higher colonizing inoculum leading to a possible increased risk of cross-transmission \[[@CR56], [@CR57]\]. Furthermore, cross-transmission was a rare event even for *K. pneumoniae* as reported previously \[[@CR27], [@CR28]\]. No data prove any difference between standard and contact precautions regarding *K. pneumoniae* cross-transmission \[[@CR58]\].

Targeted screening was also studied because the risk of ESBL-E fecal carriage is not equal for every in-patient in ICU \[[@CR59]\]. This targeted strategy has been confirmed to be as efficient as the systematic one with exposure to antibiotics within the preceding 3 months, hospitalization within the preceding year, admission of another hospital department with a hospital stay of more than 5 days, immunosuppression, chronic dialysis, transfer from rehabilitation, long-term-care unit or nursing home, and travel abroad within 1 year as targeted risk factors. Results were consistent with those of another study which considered transfer from another unit or hospital as risk factors and did not find any association with more third-generation cephalosporin (3CG)-resistant infections (ESBL or production of cephalosporinase) \[[@CR60]\]. Nevertheless, the targeted strategy has not been compared to the complete cessation of screening and there is so no proof of its relevance.

Even if the relevance of universal screening and of contact precautions is questioned, it should not be interpreted as a lax signal. Once again, high compliance with systematic standard precautions, especially hand hygiene, permanent surveillance of nosocomial ESBL-E infection outbreak, and antimicrobial stewardship are fully needed \[[@CR61]\].

Treatment of subsequent infections {#Sec13}
----------------------------------

Several studies aimed to identify reliable risk factors to predict subsequent ESBL-E infections. In non-ICU patients, severity at admission and colonization with *Enterobacter* sp. or *K. pneumoniae*; referral from a medical ward, nursing home, or rehabilitation center; previous fluoroquinolone treatment; extracorporeal membrane oxygenation; and the absence of prior positive ESBL-E rectal swab culture were identified as risk factors \[[@CR62]\]. Despite these identified risk factors, it remains difficult to predict which patient is infected with an ESBL-E or not, especially in ICU \[[@CR39]\]. The effect of BLI use prior to infection among ESBL-E fecal carriers remains unclear \[[@CR37], [@CR63]\]. Available data focus on VAP and BSI as they are the most frequent ICU-acquired infections and as the distinction between urinary tract infection and urinary colonization in catheterized patients can be seriously challenging.

As described for the risk of transmission, *K. pneumoniae* could be at increased risk of subsequent infections in colonized patients compared with other *Enterobacteriaceae* \[[@CR55], [@CR56], [@CR64]\]. Moreover, no significant difference in hospital mortality in non-ICU patients has been found between *E. coli* and *K. pneumoniae* (ESBL *E. coli* 23.8% vs ESBL *K. pneumoniae* 27.1%, *p* = 0.724) \[[@CR65]\]. Once again, the role of the bacteria itself or of the host's condition is still unclear \[[@CR56]\]. ESBL-E carriage, *a fortiori* for *K. pneumoniae*, could be a major reflection of the host frailty. The fact that adequate empirical therapy does not have a clear impact on ESBL-E infections contrary to the host's condition supports this hypothesis \[[@CR66]--[@CR69]\]. The more recent study on the field is the only randomized controlled trial available and did not manage to prove the non-inferiority of piperacillin-tazobactam compared with meropenem for the treatment of BSI due to 3CG-resistant *E.coli* or *K. pneumoniae* \[[@CR69]\]. Nevertheless, despite the quality of this study, some limitations apply to the conclusions of this study which should be interpreted cautiously \[[@CR70]\]. Further studies are urgently needed to address this issue. Therefore, systematic carbapenem use among subsequently infected ESBL-E carriers could be questioned. In that case, main alternative candidates would be combinations such as piperacillin-tazobactam, new beta-lactams as ceftolozane-tazobactam or ceftazidime-avibactam, and combination with aminoglycosides \[[@CR71]--[@CR74]\]. Those strategies need to be validated but would allow carbapenems spare without the need of systematic ESBL-E fecal carriage screening.

Selective decontamination {#Sec14}
-------------------------

Selective decontamination is an attractive approach but, as previously described, its efficacy for ESBL-E decontamination still needs to be proven. Moreover, some concerns are already raised about the emergence of resistance to used antimicrobials such as colistin and tobramycin \[[@CR75]--[@CR77]\]. One of these studies even showed the emergence of ESBL-E when 3CG are used for selective decontamination \[[@CR77]\]. Regarding a non-ICU setting, the major study was a single-center trial with 54 ESBL-E carriers involved which assessed colistin and neomycin plus nitrofurantoin to successfully decolonize patients during the treatment but not 7 days after treatment cessation. Furthermore, no clinical outcome was reported \[[@CR78]\].

Another approach to eradicate ESBL-E fecal carriage would be to cope with the effects of critical illness and antimicrobial therapy on gut. In fact, major gut microbiota modifications occur during hospitalization, *a fortiori* in ICU, and some of these modifications are associated ESBL-E fecal carriage \[[@CR79], [@CR80]\]. Cases of FMT to eradicate ESBL-E carriage have been reported \[[@CR81], [@CR82]\]. This approach is now being investigated in non-ICU patients. A proof-of-principle study included 15 patients to receive one FMT (among whom 7 received a second one) and suggested that FMT could be an effective treatment in patients carrying ESBL-E with several possible factors of response to therapy, such as donor-recipient microbiota match and number of FMTs \[[@CR83]\]. A randomized, open-label, superiority trial in four tertiary care centers showed a non-significant decolonization success of 1.7 \[95% CI 0.4--6.4\] for a 5-day course of oral antibiotics followed by FMT, but the study failed to achieve the planned sample size for logistical and regulatory reasons making firm conclusions regarding efficacy difficult \[[@CR84]\]. Moreover, fecal transplantation is not always well accepted by the patients and their siblings and concerns exist about gut permeability among critically ill patients \[[@CR85]\]. A "soft decolonization" approach by probiotics could be a more feasible option. Nevertheless, this field has to be considered with caution and remains controversial, since there are studies with some positive effects, but also many negative studies. A major limit of previous studies is that used probiotics were "ready-to-use." A promising but still experimental approach is to tailor the probiotics by indication or even by patient. A first step forward is the identification of a four-bacteria consortium which eradicates gut colonization with vancomycin-resistant *Enterococcus faecium* in a murine model \[[@CR86]\]. Regarding ESBL-E colonization, a recent study identified *Bacteroïdes uniformis* as a possible candidate \[[@CR87]\]. FMT and "soft decolonization" by tailored probiotics have to be further investigated and shown to be effective and safe among ICU patients before it can be used in routine. Therefore, systematic ESBL-E fecal carriage screening cannot be indicated to guide non-validated therapies.

Conclusions {#Sec15}
===========

Systematic ESBL-E fecal carriage screening in ICU and contact precautions have been set up to fight against ESBL-E outbreaks. In front of a changing paradigm from clonal outbreaks in health settings to a wide dissemination in the community, systematic ESBL-E screening could not be adequate anymore to guide contact precautions. Systematic and thorough standard precautions with hand hygiene appear to be the most efficient procedures even if studies providing higher level of evidence are warranted to strongly recommend in favor of or against systematic ESBL-E fecal carriage screening in ICU to guide hygiene procedures. Systematic ESBL-E fecal carriage screening seems to increase the consumption of carbapenems without improving the patients' care and so does not seem to be beneficial as the overuse of carbapenems is associated with the expansion of carbapenem-resistant *Enterobacteriaceae*. The link between ESBL-E colonization and infection should be further investigated to better understand involved mechanisms. Selective decontamination could be a helpful approach to eradicate ESBL-E colonization, but its efficacy still needs to be demonstrated and concerns exist about the emergence of resistance to the antimicrobials used. New strategies for ESBL-E eradication modulating the gut microbiota such as FMT or a "soft decolonization" approach should be considered in future studies.
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===============

 {#Sec16}

Additional file 1:**Figure S1.** Factors questioning the relevance of systematic fecal carriage screening of ESBL-E. ESBL-E: extended-spectrum beta-lactamase-producing *Enterobacteriaceae*. ICU: intensive care unit. (DOCX 98 kb)
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